AntriaBio

AB301

Product Pipeline

AB301

AntriaBio's product candidate, AB301, is a once-weekly injectable combination of a pegylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, AntriaBio's basal insulin lead product candidate. AB301 is to be administered by subcutaneous injection and is intended for use in patients with Type 2 diabetes.

AntriaBio is currently engaged in additional ongoing preclinical studies of AB301.